Global Genomic Cancer Panel and Profiling Markets, 2023-2027: An Exploding Market as Physicians Use All the Information they Can Get in the Battle Against Cancer

Rhea-AI Summary

The global genomic cancer panel and profiling market is experiencing rapid growth as physicians increasingly utilize comprehensive data in cancer diagnosis and treatment. A recent report indicates a shift from a niche market to mainstream adoption among oncologists, highlighting the potential for premium pricing on effective diagnostics. The report provides detailed insights across 18 countries and forecasts demand for advanced testing regimes. Key players are expanding globally, with advancements in sequencing technology and significant trends impacting market dynamics. Assistance for growth estimates is provided, facilitating decision-making in clinical facilities.

Positive

• Market growth driven by increased adoption of cancer gene panels and genomic profiling.
• Report forecasts significant demand for advanced testing technologies.
• Emerging opportunities for premium pricing on effective cancer diagnostics.
• Global expansion among key players in the genomic cancer panel market.
• Advancements in sequencing technology reducing costs.

Negative

• None.

DUBLIN, Feb. 9, 2023 /PRNewswire/ -- The "Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2023-2027" report has been added to  ResearchAndMarkets.com's offering.

The market is exploding as physicians use all the information they can get in the battle against cancer. While Pharmaceutical Companies see the potential to make nearly any therapy viable. The report has data on how to test volumes have grown for the biggest players. Find out how this new way of understanding cancer will change cancer diagnostics forever.

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using the information on the hundreds of genes related to cancer.

Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for positions in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with an enormous opportunity where the right diagnostic with the right support can command premium pricing. And science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

Hundreds of pages of information including a complete list of United States Medicare Fee Payment Schedules to help understand the new pricing for cancer panels. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

1. Market Guides
1.1. Cancer Panel Market-Strategic Situation Analysis
1.2. Large Comprehensive Cancer Panel Market-Situation Analysis
1.3. Guide for Executives, Marketing, Sales and Business Development Staff
1.4. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition
2.1. What are Cancer Gene Panels and Profiling?
2.2. The Sequencing Revolution
2.3. Market Definition
2.3.1. Revenue Market Size
2.4. Methodology
2.5. Perspective: Healthcare and the IVD Industry
2.5.1. Global Healthcare Spending
2.5.2. Spending on Diagnostics
2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview
3.1. Players in a Dynamic Market
3.1.1. Academic Research Lab
3.1.2. Diagnostic Test Developer
3.1.3. Instrumentation Supplier
3.1.4. Chemical/Reagent Supplier
3.1.5. Pathology Supplier
3.1.6. Independent Clinical Laboratory
3.1.7. Public National/regional Laboratory
3.1.8. Hospital Laboratory
3.1.9. Physicians Office Lab (POLS)
3.1.10. Audit Body
3.1.11. Certification Body
3.2. Oncogenomics
3.2.1. Carcinogenesis
3.2.2. Chromosomes, Genes and Epigenetics
3.2.2.1. Chromosomes
3.2.2.2. Genes
3.2.2.3. Epigenetics
3.2.3. Cancer Genes
3.2.4. Germline vs Somatic
3.2.5. Gene Panels, Single Gene Assays and Multiplexing
3.2.6. Genomic Profiling
3.2.7. The Comprehensive Assay
3.2.8. Changing Clinical Role
3.2.9. The Cancer Screening Market Opportunity
3.3. Cancer Management vs. Diagnosis
3.3.1. The Role of Risk Assessment
3.3.2. Diagnosis
3.3.3. Managing
3.3.4. Monitoring
3.4. Phases of Adoption - Looking into The Future
3.5. Structure of Industry Plays a Part
3.5.1. Hospital Testing Share
3.5.2. Economies of Scale
3.5.2.1. Hospital vs. Central Lab
3.5.3. Physician Office Lab's
3.5.4. Physician's and POCT
3.6. Currently Available Large Comprehensive Assays
3.7. Pricing Profiling vs. Whole Exome (or Genome) Sequencing
3.7.1. Medicare Profile Pricing
3.7.2. Whole Exome Sequencing

4. Market Trends
4.1. Factors Driving Growth
4.1.1. Level of Care
4.1.2. Companion Dx
4.1.3. Immuno-oncology
4.1.4. Liability
4.1.5. The Aging Effect
4.2. Factors Limiting Growth
4.2.1. State of knowledge
4.2.2. Genetic Blizzard
4.2.3. Protocol Resistance
4.2.4. Regulation and coverage
4.3. Instrumentation and Automation
4.3.1. Instruments Key to Market Share
4.3.2. Bioinformatics Plays a Role
4.4. Diagnostic Technology Development
4.4.1. Next Generation Sequencing Fuels a Revolution
4.4.2. Single Cell Genomics Changes the Picture
4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
4.4.4. CGES Testing, A Brave New World
4.4.5. Biochips/Giant magneto resistance based assay

5. Cancer Panels & Profiles Recent Developments
5.1. Recent Developments - Importance and How to Use This Section
5.1.1. Importance of These Developments
5.1.2. How to Use This Section
5.2. Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy
5.3. Thermo Fisher Introduces Homologous Score for Cancer Profiling
5.4. Genomic Test IDs Cancer Cells Early
5.5. Caris Life Sciences to Offer Molecular Profiling Services
5.6. Geneseeq to Build Lab for Cancer Profiling in Brazil
5.7. Genetron Health Adds New Assays to Pipeline
5.8. Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay
5.9. Guardant Health Receives Medicare Coverage for Guardant360 TissueNextT Test
5.10. Cancer Screening Launch Approaches, Guardant Health Plans New Comprehensive Assay
5.11. Thermo Fisher, Oncocyte Ink Deal for Cancer IVDs
5.12. Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role
5.13. Labcorp, CCORN Partner for Precision Oncology
5.14. Dante Labs Acquires Cambridge Cancer Genomics
5.15. Celemics, Strand Partner on Integrated Platform for NGS Analysis
5.16. Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries
5.17. Burning Rock Revenues Rise
5.18. Caris Life Sciences to Expand Liquid Biopsy Testing
5.19. OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence
5.20. Intermountain and Myriad Combine Test Offering
5.21. Illumina, Geneseeq to Offer Cancer Testing Kits in China
5.22. Exact Sciences to Offer End-to-End Cancer Testing
5.23. Guardant Health Turns to Tumor Tissue Sequencing
5.24. Tempus Inks Oncology Testing Collaboration With Bayer
5.25. Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
5.26. Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
5.27. Metastatic Cancer Markers Identified in Clinical WGS Study
5.28. Stitch Bio Bets on CRISPR Tech
5.29. Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
5.30. Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
5.31. Progress, Challenges in Liquid Biopsy Reimbursement
5.32. Israeli Startup Curesponse Raises $6M
5.33. Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
5.34. MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
5.35. NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
5.36. Germline Results Guides Precision Therapy in Advanced Cancer
5.37. FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
5.38. ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
5.39. Labs Reporting Cancer Risk Mutations from Tumor Testing
5.40. Users Begin Integrating Genomics Data for Clinical Decision Support
5.41. Fujitsu Improves Efficiency in Cancer Genomic Medicine

6. Profiles of Key Players

• 10x Genomics, Inc.
• Abbott Laboratories
• AccuraGen Inc.
• Adaptive Biotechnologies
• Aethlon Medical
• Agilent/Dako
• Anchor Dx
• ANGLE plc
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics
• Becton, Dickinson and Company
• BGI Genomics Co. Ltd
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• BioGenex
• BioIVT
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc
• Bio-Reference Laboratories
• Bio-Techne
• Bioview
• Bolidics
• Boreal Genomics
• Bristol-Myers Squibb
• Burning Rock
• Cardiff Oncology
• Caris Molecular Diagnostics
• Castle Biosciences, Inc.
• Celemics
• CellMax Life
• Cepheid (Danaher)
• Charles River Laboratories
• Circulogene
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Diasorin S.p.A.
• Element Biosciences
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Eurofins Scientific
• Exact Sciences
• Fabric Genomics
• Fluxion Biosciences
• Freenome
• FUJIFILM Wako Diagnostics
• GeneFirst Ltd.
• Genetron Holdings
• GenomOncology
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• HeiScreen
• Helomics
• HTG Molecular Diagnostics
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• Integrated Diagnostics
• Invitae Corporation
• Invivogen
• Invivoscribe
• Janssen Diagnostics
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics/Myriad RBM
• NantHealth, Inc.
• Natera
• NeoGenomics
• NGeneBio
• Novogene Bioinformatics Technology Co., Ltd.
• Oncocyte
• OncoDNA
• Ortho Clinical Diagnostics
• Oxford Nanopore Technologies
• Panagene
• Perkin Elmer
• Personal Genome Diagnostics
• Personalis
• Precipio
• Precision Medicine Group
• PrecisionMed
• Promega
• Qiagen
• Rarecells SAS
• RareCyte
• Roche Molecular Diagnostics
• Screencell
• Sense Biodetection
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• Singulomics
• SkylineDx
• Standard BioTools
• Stilla Technologies
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific Inc.
• Todos Medical
• Ultima Genomics
• Variantyx
• Veracyte
• Volition
• Vortex Biosciences
• Vyant Bio
• Singular Genomics
• SkylineDx
• Standard BioTools
• Sure Genomics, Inc.
• Sysmex
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific Inc.
• Ultima Genomics
• Variantyx
• Volition

For more information about this report visit https://www.researchandmarkets.com/r/mdg07o-cancer?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets 
Laura Wood, Senior Manager 
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900 

U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716

Logo: http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

 

View original content:https://www.prnewswire.com/news-releases/global-genomic-cancer-panel-and-profiling-markets-2023-2027-an-exploding-market-as-physicians-use-all-the-information-they-can-get-in-the-battle-against-cancer-301743015.html

SOURCE Research and Markets

FAQ

What is the growth trend in the genomic cancer panel market by GTH?

The genomic cancer panel market is growing rapidly, transitioning from a niche to a mainstream market as oncologists adopt genomic profiling in diagnostics.

How will the genomic profiling market change cancer diagnostics by 2027?

The market is expected to change cancer diagnostics through the widespread use of comprehensive genomic data, facilitating better-targeted therapies.

What does the report on genomic cancer panels cover?

The report covers market size forecasts, strategic analyses, and insights across 18 countries, addressing the growth and dynamics of the genomic cancer panel market.

What factors are driving the growth of cancer diagnostics?

Key factors include technological advancements in sequencing, increased awareness, and demand for personalized medicine in oncology.

How is GTH positioned in the genomic profiling landscape?

GTH is positioned as a significant player in the genomic profiling market, leveraging technological advancements and expanding services globally.